Dr. Behnam Khaleghi Receives Congressional Recognition from U.S. Congressman Ken Calvert
Dr. Behnam Khaleghi, board-certified rheumatologist at Pacific Rheumatology Medical Center (PRMC), receives a certificate of special recognition from congressman Ken Calvert for outstanding and invaluable service to the community.
The ceremony took place in Riverside CA. Dr. Khaleghi earned his medical degree and graduated with honors at Shahid Beheshti University in Tehran, one of the most prestigious academic institutions in Iran. He then went on to complete his internship and residency in internal medicine at St. Barnabas Hospital in the Bronx, New York, before completing a rheumatology fellowship at Cooper University Hospital in Camden, New Jersey.
“I am humbled and honored to receive this certificate of recognition,” said Dr. K, “and it represents a level of excellence in care that myself and the rest of the team here at Pacific Rheumatology Medical Center will continue to strive towards as we offer the communities of Orange County our services.” This award is just one of many awarded to Dr. Khaleghi and the PRMC team in recent months, the latest being Dr. K’s Castle Connolly Top Doctor 2021 award, won for the second year in a row.
About Pacific Rheumatology Medical Center
With two state-of-the-art facilities in Tustin and Laguna Hills, California, Pacific Rheumatology Medical Center provides comprehensive, patient-centered care of adult rheumatic diseases. Board-certified rheumatologist Behnam Khaleghi, MD, offers treatments and care for men and women of all ages with all types of musculoskeletal diseases. Dr. Khaleghi treats patients with a wide range of conditions, including all types of arthritis and complex inflammatory issues. He also offers regenerative medicine treatments such as stem cell therapy and platelet-rich plasma (PRP) injections. In addition to in-office anti-inflammatory supplements, such as CBD oil, Dr. Khaleghi prescribes the highest-quality medications to treat rheumatoid arthritis, including Remicade®, Orencia®, Actemra®, Simponi®, and rituximab.